Luke J Norman1, Kristin A Mannella1, Huan Yang1, Mike Angstadt1, James L Abelson1, Joseph A Himle1, Kate D Fitzgerald1, Stephan F Taylor1. 1. Department of Psychiatry, Medical School, University of Michigan, Ann Arbor (Norman, Mannella, Yang, Angstadt, Abelson, Himle, Fitzgerald, Taylor); Neurobehavioral Clinical Research Section, Social and Behavioral Research Branch, National Human Genome Research Institute, Bethesda, Md. (Norman); Second Xiangya Hospital, Central South University, Changsha, China (Yang).
Abstract
OBJECTIVE: The authors sought to examine whether brain activity is associated with treatment response to cognitive-behavioral therapy (CBT) in adolescents and adults with obsessive-compulsive disorder (OCD), and whether any associations are treatment specific relative to an active control psychotherapy (stress management therapy; SMT). METHODS: Eighty-seven patients with OCD (age range 12-45 years; 57 female, 39 medicated) were randomly assigned to receive 12 weeks of CBT or SMT. Prior to treatment, functional MRI scans were conducted in patients performing an incentive flanker task, which probes brain activation to both cognitive control and reward processing. Voxelwise linear mixed-effects models examined whether baseline brain activation was differentially associated with change in scores on the Yale-Brown Obsessive Compulsive Scale (standard or Children's version) over the course of CBT or SMT treatment. RESULTS: Within the CBT group, a better treatment response was significantly associated with greater pretreatment activation within the right temporal lobe and rostral anterior cingulate cortex during cognitive control and within the ventromedial prefrontal, orbitofrontal, lateral prefrontal, and amygdala regions during reward processing. In contrast, reduced pretreatment activation within a largely overlapping set of regions was significantly associated with a better treatment response to SMT. CONCLUSIONS: The study findings demonstrate that associations between brain activation and treatment response were treatment specific to CBT relative to a control psychotherapy and that these associations were stable from adolescence to mature adulthood. Such treatment-specific associations are important for the development of biomarkers to personalize treatment in OCD.
OBJECTIVE: The authors sought to examine whether brain activity is associated with treatment response to cognitive-behavioral therapy (CBT) in adolescents and adults with obsessive-compulsive disorder (OCD), and whether any associations are treatment specific relative to an active control psychotherapy (stress management therapy; SMT). METHODS: Eighty-seven patients with OCD (age range 12-45 years; 57 female, 39 medicated) were randomly assigned to receive 12 weeks of CBT or SMT. Prior to treatment, functional MRI scans were conducted in patients performing an incentive flanker task, which probes brain activation to both cognitive control and reward processing. Voxelwise linear mixed-effects models examined whether baseline brain activation was differentially associated with change in scores on the Yale-Brown Obsessive Compulsive Scale (standard or Children's version) over the course of CBT or SMT treatment. RESULTS: Within the CBT group, a better treatment response was significantly associated with greater pretreatment activation within the right temporal lobe and rostral anterior cingulate cortex during cognitive control and within the ventromedial prefrontal, orbitofrontal, lateral prefrontal, and amygdala regions during reward processing. In contrast, reduced pretreatment activation within a largely overlapping set of regions was significantly associated with a better treatment response to SMT. CONCLUSIONS: The study findings demonstrate that associations between brain activation and treatment response were treatment specific to CBT relative to a control psychotherapy and that these associations were stable from adolescence to mature adulthood. Such treatment-specific associations are important for the development of biomarkers to personalize treatment in OCD.
Authors: Jonathan Downar; Joseph Geraci; Tim V Salomons; Katharine Dunlop; Sarah Wheeler; Mary Pat McAndrews; Nathan Bakker; Daniel M Blumberger; Zafiris J Daskalakis; Sidney H Kennedy; Alastair J Flint; Peter Giacobbe Journal: Biol Psychiatry Date: 2013-11-28 Impact factor: 13.382
Authors: Marcelo Q Hoexter; Darin D Dougherty; Roseli G Shavitt; Carina C D'Alcante; Fabio L S Duran; Antonio C Lopes; Juliana B Diniz; Marcelo C Batistuzzo; Karleyton C Evans; Rodrigo A Bressan; Geraldo F Busatto; Euripedes C Miguel Journal: Eur Neuropsychopharmacol Date: 2012-07-27 Impact factor: 4.600
Authors: A L Brody; S Saxena; J M Schwartz; P W Stoessel; K Maidment; M E Phelps; L R Baxter Journal: Psychiatry Res Date: 1998-11-09 Impact factor: 3.222
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Petros Skapinakis; Deborah M Caldwell; William Hollingworth; Peter Bryden; Naomi A Fineberg; Paul Salkovskis; Nicky J Welton; Helen Baxter; David Kessler; Rachel Churchill; Glyn Lewis Journal: Lancet Psychiatry Date: 2016-06-16 Impact factor: 27.083
Authors: Alessandro S De Nadai; Kate D Fitzgerald; Luke J Norman; Stefanie R Russman Block; Kristin A Mannella; Joseph A Himle; Stephan F Taylor Journal: Neuropsychopharmacology Date: 2022-06-09 Impact factor: 7.853
Authors: Laura B Bragdon; Goi Khia Eng; Amanda Belanger; Katherine A Collins; Emily R Stern Journal: Front Psychiatry Date: 2021-08-25 Impact factor: 5.435